To include your compound in the COVID-19 Resource Center, submit it here.

ABX-EGF: ABGX and partner Immunex Corp. (IMNX, Seattle, Wash.) began a U.S. open-label Phase II trial of ABX-EGF as monotherapy in up to 100 metastatic colorect

Abgenix Inc. (ABGX), Fremont, Calif.
Product: ABX-EGF
Business: Cancer
Therapeutic

Read the full 100 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE